Cargando…
Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial
OBJECTIVE: To investigate whether increased fixed carbidopa doses of 65 or 105 mg (ODM-101/65 and ODM-101/105) in combination with 75, 100, 125, or 150 mg of levodopa and 200 mg of entacapone might improve “off” time in fluctuating Parkinson disease (PD) compared to the standard combination of 4:1 l...
Autores principales: | Trenkwalder, Claudia, Kuoppamäki, Mikko, Vahteristo, Mikko, Müller, Thomas, Ellmén, Juha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453771/ https://www.ncbi.nlm.nih.gov/pubmed/30824559 http://dx.doi.org/10.1212/WNL.0000000000007173 |
Ejemplares similares
-
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015) -
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022) -
Levodopa/carbidopa and entacapone in the treatment of
Parkinson’s disease: efficacy, safety and patient
preference
por: Müller, Thomas
Publicado: (2009) -
Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010) -
Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
por: Öthman, Mezin, et al.
Publicado: (2021)